Apparently smoothing over past problems and threats of a lawsuit, Paradigm Genetics announced that former president and CEO John Ryals has left the company’s board of directors.
GPC Biotech fills up its clinical development stable in Princeton, NJ: Edward McNiff is VP of pharmaceutical development; Thomas McKearn is VP of medical affairs; Michael Petrone is VP of clinical operations; and John Slayback is director of analytical and formulation development and outsourcing.
Rubicon Genomics, an amplification-based genomics company in Ann Arbor, Mich., kicks off its scientific advisory board with the first three members: Michael Boehnke, director of the University of Michigan’s Center for Statistical Genetics; Anthony Czarnik, CSO of Sensors for Medicine and Science; and Bruce Roe, director of the University of Oklahoma’s Advanced Center for Genome Technology.
Geoffrey Yarranton becomes executive vice president of R&D at Redwood City, Calif.’s Deltagen after leaving his post at Coulter Pharmaceutical. Peter Myers, meanwhile, resigns from his job as exec VP of Deltagen research labs.
Caprion Pharmaceuticals appoints Daniel Chelsky, previously with PerkinElmer division BioSignal Packard, as chief scientific officer.
Epoch Biosciences hires Cy Cabradilla to the new position of operations VP. Before heading to the Bothell, Wash., company, Cabradilla was vice president of genomics for BioSource International, a reagent systems firm.
Aidan Courtney becomes CEO of Aneda, in which he was an initial investor and has been its part-time commercial director.
SignalGene announces the resignation of CFO and senior veep Claude Monette. Doris Belzile, formerly the company’s vice president of finance and administration, becomes CFO.
All roads lead out of GSK:
Former chief science and technology officer for GlaxoSmithKline James Niedel joins venture capital firm the Sprout Group as venture partner for healthcare technology investments. Neil Thompson, who was director of Glaxo’s immunology platform, leaves to become vice president of biology at high-throughput crystallography company Astex Technology in Cambridge, UK.
Marc Vasseur steps in as CEO and chairman of Genset, following the resignation of Andre Pernet. Vasseur is a cofounder of the company, was its chief biology officer, and recently served as president of Institut Pasteur spinout Pasteur-Mediavita.